Global and United States Radioimmunotherapy Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Radioimmunotherapy Market Size Growth Rate by Type: 2020 VS 2026
  • 1.2.2 Non Hodgkin Lymphoma (NHL)
  • 1.2.3 Follicular Lymphoma
  • 1.2.4 Solid Tumors
  • 1.2.5 Breast Cancer
  • 1.2.6 Ovarian Cancer
  • 1.2.7 Osteosarcoma
  • 1.2.8 Neuroblastoma
  • 1.2.9 Prostate Cancer
• 1.3 Market by Application
  • 1.3.1 Global Radioimmunotherapy Market Share by Application: 2020 VS 2026
  • 1.3.2 Tumor Antigens
  • 1.3.3 Radionuclides
  • 1.3.4 Antibodies
• 1.4 Study Objectives
• 1.5 Years Considered

2 Global Growth Trends

• 2.1 Global Radioimmunotherapy Market Perspective (2015-2026)
• 2.2 Global Radioimmunotherapy Growth Trends by Regions
  • 2.2.1 Radioimmunotherapy Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Radioimmunotherapy Historic Market Share by Regions (2015-2020)
  • 2.2.3 Radioimmunotherapy Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Radioimmunotherapy Players by Market Size
  • 3.1.1 Global Top Radioimmunotherapy Players by Revenue (2015-2020)
  • 3.1.2 Global Radioimmunotherapy Revenue Market Share by Players (2015-2020)
• 3.2 Global Radioimmunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Players Covered: Ranking by Radioimmunotherapy Revenue
• 3.4 Global Radioimmunotherapy Market Concentration Ratio
  • 3.4.1 Global Radioimmunotherapy Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Radioimmunotherapy Revenue in 2019
• 3.5 Key Players Radioimmunotherapy Area Served
• 3.6 Key Players Radioimmunotherapy Product Solution and Service
• 3.7 Date of Enter into Radioimmunotherapy Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Radioimmunotherapy Breakdown Data by Type (2015-2026)

• 4.1 Global Radioimmunotherapy Historic Market Size by Type (2015-2020)
• 4.2 Global Radioimmunotherapy Forecasted Market Size by Type (2021-2026)

5 Radioimmunotherapy Breakdown Data by Application (2015-2026)

• 5.1 Global Radioimmunotherapy Historic Market Size by Application (2015-2020)
• 5.2 Global Radioimmunotherapy Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Radioimmunotherapy Market Size (2015-2026)
• 6.2 North America Radioimmunotherapy Market Size by Type (2015-2020)
• 6.3 North America Radioimmunotherapy Market Size by Application (2015-2020)
• 6.4 North America Radioimmunotherapy Market Size by Country (2015-2020)
  • 6.4.1 United States
  • 6.4.2 Canada

7 Europe

• 7.1 Europe Radioimmunotherapy Market Size (2015-2026)
• 7.2 Europe Radioimmunotherapy Market Size by Type (2015-2020)
• 7.3 Europe Radioimmunotherapy Market Size by Application (2015-2020)
• 7.4 Europe Radioimmunotherapy Market Size by Country (2015-2020)
  • 7.4.1 Germany
  • 7.4.2 France
  • 7.4.3 U.K.
  • 7.4.4 Italy
  • 7.4.5 Russia
  • 7.4.6 Nordic
  • 7.4.7 Rest of Europe

8 China

• 8.1 China Radioimmunotherapy Market Size (2015-2026)
• 8.2 China Radioimmunotherapy Market Size by Type (2015-2020)
• 8.3 China Radioimmunotherapy Market Size by Application (2015-2020)
• 8.4 China Radioimmunotherapy Market Size by Region (2015-2020)
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 South Korea
  • 8.4.4 Southeast Asia
  • 8.4.5 India
  • 8.4.6 Australia
  • 8.4.7 Rest of Asia-Pacific

9 Japan

• 9.1 Japan Radioimmunotherapy Market Size (2015-2026)
• 9.2 Japan Radioimmunotherapy Market Size by Type (2015-2020)
• 9.3 Japan Radioimmunotherapy Market Size by Application (2015-2020)
• 9.4 Japan Radioimmunotherapy Market Size by Country (2015-2020)
  • 9.4.1 Mexico
  • 9.4.2 Brazil

10 Southeast Asia

• 10.1 Southeast Asia Radioimmunotherapy Market Size (2015-2026)
• 10.2 Southeast Asia Radioimmunotherapy Market Size by Type (2015-2020)
• 10.3 Southeast Asia Radioimmunotherapy Market Size by Application (2015-2020)
• 10.4 Southeast Asia Radioimmunotherapy Market Size by Country (2015-2020)
  • 10.4.1 Turkey
  • 10.4.2 Saudi Arabia
  • 10.4.3 UAE
  • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

• 11.1 Bayer Healthcare Pharmaceuticals
  • 11.1.1 Bayer Healthcare Pharmaceuticals Company Details
  • 11.1.2 Bayer Healthcare Pharmaceuticals Business Overview
  • 11.1.3 Bayer Healthcare Pharmaceuticals Radioimmunotherapy Introduction
  • 11.1.4 Bayer Healthcare Pharmaceuticals Revenue in Radioimmunotherapy Business (2015-2020))
  • 11.1.5 Bayer Healthcare Pharmaceuticals Recent Development
• 11.2 BioSynthema
  • 11.2.1 BioSynthema Company Details
  • 11.2.2 BioSynthema Business Overview
  • 11.2.3 BioSynthema Radioimmunotherapy Introduction
  • 11.2.4 BioSynthema Revenue in Radioimmunotherapy Business (2015-2020)
  • 11.2.5 BioSynthema Recent Development
• 11.3 Clarity Pharmaceuticals
  • 11.3.1 Clarity Pharmaceuticals Company Details
  • 11.3.2 Clarity Pharmaceuticals Business Overview
  • 11.3.3 Clarity Pharmaceuticals Radioimmunotherapy Introduction
  • 11.3.4 Clarity Pharmaceuticals Revenue in Radioimmunotherapy Business (2015-2020)
  • 11.3.5 Clarity Pharmaceuticals Recent Development
• 11.4 Curasight
  • 11.4.1 Curasight Company Details
  • 11.4.2 Curasight Business Overview
  • 11.4.3 Curasight Radioimmunotherapy Introduction
  • 11.4.4 Curasight Revenue in Radioimmunotherapy Business (2015-2020)
  • 11.4.5 Curasight Recent Development
• 11.5 Endocyte
  • 11.5.1 Endocyte Company Details
  • 11.5.2 Endocyte Business Overview
  • 11.5.3 Endocyte Radioimmunotherapy Introduction
  • 11.5.4 Endocyte Revenue in Radioimmunotherapy Business (2015-2020)
  • 11.5.5 Endocyte Recent Development
• 11.6 Immunomedics
  • 11.6.1 Immunomedics Company Details
  • 11.6.2 Immunomedics Business Overview
  • 11.6.3 Immunomedics Radioimmunotherapy Introduction
  • 11.6.4 Immunomedics Revenue in Radioimmunotherapy Business (2015-2020)
  • 11.6.5 Immunomedics Recent Development
• 11.7 Molecular Insight Pharmaceuticals
  • 11.7.1 Molecular Insight Pharmaceuticals Company Details
  • 11.7.2 Molecular Insight Pharmaceuticals Business Overview
  • 11.7.3 Molecular Insight Pharmaceuticals Radioimmunotherapy Introduction
  • 11.7.4 Molecular Insight Pharmaceuticals Revenue in Radioimmunotherapy Business (2015-2020)
  • 11.7.5 Molecular Insight Pharmaceuticals Recent Development
• 11.8 Nordic Nanovector
  • 11.8.1 Nordic Nanovector Company Details
  • 11.8.2 Nordic Nanovector Business Overview
  • 11.8.3 Nordic Nanovector Radioimmunotherapy Introduction
  • 11.8.4 Nordic Nanovector Revenue in Radioimmunotherapy Business (2015-2020)
  • 11.8.5 Nordic Nanovector Recent Development
• 11.9 PDL Biopharma
  • 11.9.1 PDL Biopharma Company Details
  • 11.9.2 PDL Biopharma Business Overview
  • 11.9.3 PDL Biopharma Radioimmunotherapy Introduction
  • 11.9.4 PDL Biopharma Revenue in Radioimmunotherapy Business (2015-2020)
  • 11.9.5 PDL Biopharma Recent Development
• 11.10 Philogen
  • 11.10.1 Philogen Company Details
  • 11.10.2 Philogen Business Overview
  • 11.10.3 Philogen Radioimmunotherapy Introduction
  • 11.10.4 Philogen Revenue in Radioimmunotherapy Business (2015-2020)
  • 11.10.5 Philogen Recent Development
• 11.11 RadioMedix
  • 10.11.1 RadioMedix Company Details
  • 10.11.2 RadioMedix Business Overview
  • 10.11.3 RadioMedix Radioimmunotherapy Introduction
  • 10.11.4 RadioMedix Revenue in Radioimmunotherapy Business (2015-2020)
  • 10.11.5 RadioMedix Recent Development
• 11.12 Stella Pharma
  • 10.12.1 Stella Pharma Company Details
  • 10.12.2 Stella Pharma Business Overview
  • 10.12.3 Stella Pharma Radioimmunotherapy Introduction
  • 10.12.4 Stella Pharma Revenue in Radioimmunotherapy Business (2015-2020)
  • 10.12.5 Stella Pharma Recent Development
• 11.13 Telix Pharmaceuticals
  • 10.13.1 Telix Pharmaceuticals Company Details
  • 10.13.2 Telix Pharmaceuticals Business Overview
  • 10.13.3 Telix Pharmaceuticals Radioimmunotherapy Introduction
  • 10.13.4 Telix Pharmaceuticals Revenue in Radioimmunotherapy Business (2015-2020)
  • 10.13.5 Telix Pharmaceuticals Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Disclaimer